Cancer biotech launches on NASDAQ

Israel’s UroGen Pharma has three treatments for the treatment of cancers of the urinary system (bladder and kidneys). It has just raised $58.2 million on NASDAQ. UroGen’s MitoGel treatment for Upper Tract Urothelial Carcinoma has received Orphan status from the US FDA.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

One Response to Cancer biotech launches on NASDAQ

  1. Pingback: Breakthrough treatment for urinary tract cancer - Israel Active

Leave a Reply

Your email address will not be published. Required fields are marked *